Show simple item record

dc.contributor.authorYshii, Lidia
dc.contributor.authorPasciuto, Emanuela
dc.contributor.authorBielefeld, Pascal
dc.contributor.authorMascali, Loriana
dc.contributor.authorLemaitre, Pierre
dc.contributor.authorMarino, Marika
dc.contributor.authorDooley, James
dc.contributor.authorKouser, Lubna
dc.contributor.authorVerschoren, Stijn
dc.contributor.authorLagou, Vasiliki
dc.contributor.authorKemps, Hannelore
dc.contributor.authorGervois, Pascal
dc.contributor.authorde Boer, Antina
dc.contributor.authorBurton, Oliver T
dc.contributor.authorWahis, Jérôme
dc.contributor.authorVerhaert, Jens
dc.contributor.authorTareen, Samar HK
dc.contributor.authorRoca, Carlos P
dc.contributor.authorSingh, Kailash
dc.contributor.authorWhyte, Carly E
dc.contributor.authorKerstens, Axelle
dc.contributor.authorCallaerts-Vegh, Zsuzsanna
dc.contributor.authorPoovathingal, Suresh
dc.contributor.authorPrezzemolo, Teresa
dc.contributor.authorWierda, Keimpe
dc.contributor.authorDashwood, Amy
dc.contributor.authorXie, Junhua
dc.contributor.authorVan Wonterghem, Elien
dc.contributor.authorCreemers, Eline
dc.contributor.authorAloulou, Meryem
dc.contributor.authorGsell, Willy
dc.contributor.authorAbiega, Oihane
dc.contributor.authorMunck, Sebastian
dc.contributor.authorVandenbroucke, Roosmarijn E
dc.contributor.authorBronckaers, Annelies
dc.contributor.authorLemmens, Robin
dc.contributor.authorDe Strooper, Bart
dc.contributor.authorVan Den Bosch, Ludo
dc.contributor.authorHimmelreich, Uwe
dc.contributor.authorFitzsimons, Carlos P
dc.contributor.authorHolt, Matthew G
dc.contributor.authorListon, Adrian
dc.date.accessioned2022-06-29T19:47:31Z
dc.date.available2022-06-29T19:47:31Z
dc.date.issued2022-06
dc.identifier.issn1529-2908
dc.identifier.other35618831
dc.identifier.otherPMC9174055
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/338542
dc.description.abstractThe ability of immune-modulating biologics to prevent and reverse pathology has transformed recent clinical practice. Full utility in the neuroinflammation space, however, requires identification of both effective targets for local immune modulation and a delivery system capable of crossing the blood-brain barrier. The recent identification and characterization of a small population of regulatory T (Treg) cells resident in the brain presents one such potential therapeutic target. Here, we identified brain interleukin 2 (IL-2) levels as a limiting factor for brain-resident Treg cells. We developed a gene-delivery approach for astrocytes, with a small-molecule on-switch to allow temporal control, and enhanced production in reactive astrocytes to spatially direct delivery to inflammatory sites. Mice with brain-specific IL-2 delivery were protected in traumatic brain injury, stroke and multiple sclerosis models, without impacting the peripheral immune system. These results validate brain-specific IL-2 gene delivery as effective protection against neuroinflammation, and provide a versatile platform for delivery of diverse biologics to neuroinflammatory patients.
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceessn: 1529-2916
dc.sourcenlmid: 100941354
dc.subjectBrain
dc.subjectAstrocytes
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectInterleukins
dc.subjectInterleukin-2
dc.subjectBiological Products
dc.subjectT-Lymphocytes, Regulatory
dc.subjectNeuroinflammatory Diseases
dc.titleAstrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation.
dc.typeArticle
dc.date.updated2022-06-29T19:47:31Z
prism.endingPage891
prism.issueIdentifier6
prism.publicationNameNat Immunol
prism.startingPage878
prism.volume23
dc.identifier.doi10.17863/CAM.85955
dcterms.dateAccepted2022-04-11
rioxxterms.versionofrecord10.1038/s41590-022-01208-z
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidPasciuto, Emanuela [0000-0002-5391-9585]
dc.contributor.orcidMarino, Marika [0000-0001-6773-6176]
dc.contributor.orcidDooley, James [0000-0003-3154-4708]
dc.contributor.orcidVerschoren, Stijn [0000-0001-6733-3481]
dc.contributor.orcidKemps, Hannelore [0000-0001-9248-1697]
dc.contributor.orcidGervois, Pascal [0000-0002-8320-1320]
dc.contributor.orcidBurton, Oliver T [0000-0003-3884-7373]
dc.contributor.orcidSingh, Kailash [0000-0002-6771-7757]
dc.contributor.orcidWhyte, Carly E [0000-0001-6556-6855]
dc.contributor.orcidCallaerts-Vegh, Zsuzsanna [0000-0001-9091-2078]
dc.contributor.orcidDashwood, Amy [0000-0002-4340-377X]
dc.contributor.orcidGsell, Willy [0000-0001-7334-6107]
dc.contributor.orcidVandenbroucke, Roosmarijn E [0000-0002-8327-620X]
dc.contributor.orcidListon, Adrian [0000-0002-6272-4085]
dc.identifier.eissn1529-2916
pubs.funder-project-idEuropean Research Council (TreatBrainDamage, TissueTregs, AstroFunc)
pubs.funder-project-idBiotechnology and Biological Sciences Research Council (BBS/E/B/000C0427, BBS/E/B/000C0428)
pubs.funder-project-idFondation Thierry Latran (Thierry Latran Foundation) (SOD-VIP)
pubs.funder-project-idInternationale Stichting Alzheimer Onderzoek (ISAO) (20190032)
cam.issuedOnline2022-05-26


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International